Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Section contains only standard non-incorporation language.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Section contains only standard non-incorporation language
- No fiscal 2026 operating results or financial metrics provided in the excerpt
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer language accompanying an investor disclosure
- No substantive business, financial, or operational update in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- Q2 product revenue $18.6M, up from $18.1M; growth driven by higher pricing rather than underlying volume
- FDA raised substantial LOTIS-5 benefit-risk concerns tied to Grade 5 events and marginal benefit, delaying the full-approval path
- LOTIS-7 enrollment completed at 100 patients, supporting potential ZYNLONTA-glofitamab expansion into 2L+ DLBCL
- Workforce reduction approximately 17%, targeting annualized cost savings of approximately $10M after trial completions
- Cash $219.1M at June 30, 2026, with runway expected into at least 2028; Q2 net loss $16.6M or $0.11 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.